Comera Life Sciences Holdings, Inc. (CMRA) News
Filter CMRA News Items
CMRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CMRA News Highlights
- CMRA's 30 day story count now stands at 3.
- Over the past 5 days, the trend for CMRA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CMRA are LAW, MS and NOV.
Latest CMRA News From Around the Web
Below are the latest news stories about COMERA LIFE SCIENCES HOLDINGS INC that investors may wish to consider to help them evaluate CMRA as an investment opportunity.
Comera Life Sciences Designates Dorothy Clarke to Board of DirectorsBy Karen E. Roman Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a company which develops biologic medicines, announced it has appointed Dorothy Clarke to its board of directors. Ms. Clarke previously held leadership roles at Johnson & Johnson for over two decades and specialized in law, regulatory affairs, compliance, and data protection, the company […] |
Comera Life Sciences Appoints Dorothy Clarke to Board of DirectorsDorothy Clarke Dorothy Clarke WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. “Dorothy’s extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way |
Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights– Final stage of technical evaluation near completion in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera’s global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technology – – Completed previously announced $4.1 million private placement of shares of Comera’s common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – WOBURN, Mass., N |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic worth checking out on Wednesday and we have all the latest news happening this morning! |
Comera Life Sciences Advancing Subcutaneous Monoclonal Antibody FormulationsBy Daniella Parra Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) said its SQore platform, which transforms intravenous biologic medicines, particularly monoclonal antibodies (mAbs), into subcutaneous formulations. The company said it reduced the viscosity of over 40 mAbs by up to 85%, addressing a common challenge in subcutaneous delivery. Additionally, there was a study where a […] |
Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery ConferenceWOBURN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today will present research demonstrating Comera’s SQore™ platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass. Yuhong Zeng, Ph.D., Director of Formulation at Comera, |
Comera Life Sciences Announces the Completion of $4.1 Million Private PlacementWOBURN, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has completed its previously announced $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders at a purchase price of $0.51125 per share. The shares ar |
These Are the ONLY 7 Penny Stocks to Consider in August 2023The most promising penny stocks combine strong share price targets and improving fundamentals moving forward. |
Comera Study Shows Caffeine’s Ability to Reduce Viscosity in AntibodiesBy Daniella Parra Comera Life Sciences Holdings (Nasdaq: CMRA) said it published data showing caffeine’s potential to reduce viscosity in subcutaneous formulations of monoclonal antibodies. The studies demonstrated caffeine’s positive influence on pharmacokinetics and its compatibility with monoclonal antibody ipilimumab, it said. “This study is an important validation of caffeine’s potential to address critical viscosity […] |